30 closest matches · ranked by relevance
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Breast Cancer Female
Primary: Measure Ki67 Index in Highly Hormone-dependent Breast Cancers vs. Those That Are Not — 7; 6; 40 Participants
Breast Cancer
Primary: Change in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration. — -2.3 Change in % of cells positive for Ki-67
Breast Cancer · Stage II Breast Cancer · Stage III Breast Cancer
Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants
Breast Cancer
Primary: Disease-free Survival (DFS) — 87.5; 85.8 percentage of patients — p=.31
Breast Cancer
Primary: Change in Proliferation Rate (Ki-67 by Immunocytochemistry) From Baseline to 6 Months — -1.5; -1.1 percentage of cells stained positive — p=0.92
Breast Cancer
Primary: Change in Ki-67 Levels From Baseline (Pre) to Day 28 (Post) Biopsy Samples — -1.3632; -1.6237 log-transformed Ki67% — p=0.6202
Breast Cancer
Primary: Disease-free Survival — 64; 71; 70 percentage of participants
Breast Cancer
Primary: Event-free Survival — 88; 89 percentage of participants — p=0.85
Breast Cancer
Primary: Clinical Response (Complete or Partial Response) Rate (Cohort A) — 62.9; 74.8; 69.1 percentage of patients
Estrogen Receptor Positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Carcinoma
Primary: Disease-free Survival — 84.7; 86.6; 89 percentage of participants — p=0.1
Breast Cancer
Primary: Overall Survival — 2.14; 2.00 years
Breast Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (All Causalities) — 92; 152; 244; 18 Participants
Breast Cancer
Primary: Objective Response Rate (ORR) Determined by Clinical Palpation — 58.9; 53.8 percentage of participants
Breast Cancer
Primary: Tolerability at One Year of Ovarian Function Suppression (OFS) Using Leuprolide and Letrozole. — 4 participants
Breast Cancer
Primary: Disease Free Survival — NA; NA Months — p=0.3150
Breast Neoplasms
Primary: Percent Change in Mammographic Density at 1 Year on Exemestane — -2.4 percent change from baseline
Post Menopausal Breast Cancer
Primary: Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades — 4; 0; 4; 195 Participants
Breast Cancer
Primary: Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence) — 6; 7…
Stage 0 Breast Cancer AJCC v6 and v7 · Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7
Primary: Percent Change in Time of Circulating Estradiol SPE in Each Arm — -89; -85; -60 percent change
Breast Neoplasms
Primary: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study — 0.90; 0.86 probability of DFS — p=0.00003
Breast Cancer
Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants
Breast Cancer
Primary: Number of Participants With Disease-free Survival (DFS) Event — 127; 170 Participants
Breast Cancer
Primary: Percent Reduction in Ki-67 Expression From Baseline to Day 15 in Tumor Biopsies — 71.4; 72.9 Percent reduction
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Breast Cancer
Primary: Time to Progression (TTP) in Women With Hormone Responsive Advanced Breast Cancer Treated With Combination of Exemestane and Fulvestrant. — 6.9 months
Breast Cancer
Primary: Change in Lumbar Density From Baseline to 12 Months — -0.036; -0.021 g/cm^2 — p=0.15
Breast Cancer
Primary: Percent Change in Lumbar Spine (L2-L4) BMD After 12 Months of Letrozole Therapy — 2.680; -3.314 Percent Change
Bone Loss · Osteoporosis · Breast Cancer
Primary: BMD of Spine by DXA — 2.269; -1.735 percentage change
Breast Cancer
Primary: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours — 103; 120 Participants — p=0.33